Pam Klein

3.3k total citations · 2 hit papers
7 papers, 2.6k citations indexed

About

Pam Klein is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Pam Klein has authored 7 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 1 paper in Surgery. Recurrent topics in Pam Klein's work include Colorectal Cancer Treatments and Studies (3 papers), HER2/EGFR in Cancer Research (2 papers) and Cancer Treatment and Pharmacology (2 papers). Pam Klein is often cited by papers focused on Colorectal Cancer Treatments and Studies (3 papers), HER2/EGFR in Cancer Research (2 papers) and Cancer Treatment and Pharmacology (2 papers). Pam Klein collaborates with scholars based in United States, Spain and Italy. Pam Klein's co-authors include David A. Ramies, Bruce E. Johnson, Vincent A. Miller, Roy S. Herbst, David H. Johnson, Xin Li, Alan Sandler, Róbert Hermann, Hai T. Tran and Mark G. Kris and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

Pam Klein

7 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

2005 1.2k citations Roy S. Herbst, Diane Prager et al. Journal of Clinical Oncology profile →
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

2005 1.2k citations David A. Eberhard, Bruce E. Johnson et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pam Klein United States	6	2.0k	2.0k	733	444	197	7	2.6k
Jean-Claude Cutz Canada	9	1.8k 0.9×	1.6k 0.8×	815 1.1×	519 1.2×	129 0.7×	12	2.4k
Ariel López-Chávez United States	18	1.9k 0.9×	2.8k 1.4×	821 1.1×	465 1.0×	151 0.8×	41	3.7k
Annetta Krebs United States	8	1.9k 0.9×	2.0k 1.0×	723 1.0×	395 0.9×	163 0.8×	8	2.8k
Allan R. Li United States	7	1.8k 0.9×	1.6k 0.8×	755 1.0×	496 1.1×	145 0.7×	7	2.3k
Teresa Morán Spain	26	1.9k 0.9×	1.6k 0.8×	1.0k 1.4×	627 1.4×	177 0.9×	130	2.7k
Zofia Piotrowska United States	26	2.1k 1.0×	1.7k 0.9×	938 1.3×	541 1.2×	199 1.0×	122	2.6k
Roberta Minari Italy	25	1.7k 0.8×	1.5k 0.7×	1.1k 1.6×	585 1.3×	208 1.1×	66	2.5k
Craig H. Reynolds United States	21	1.3k 0.7×	1.3k 0.7×	468 0.6×	279 0.6×	138 0.7×	57	2.0k
Michèle Beau‐Faller France	22	1.6k 0.8×	1.3k 0.7×	758 1.0×	554 1.2×	156 0.8×	61	2.1k
Hai‐Yan Tu China	23	2.4k 1.1×	2.2k 1.1×	695 0.9×	716 1.6×	152 0.8×	114	3.1k

Countries citing papers authored by Pam Klein

Since Specialization

Citations

This map shows the geographic impact of Pam Klein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pam Klein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pam Klein more than expected).

Fields of papers citing papers by Pam Klein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pam Klein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pam Klein. The network helps show where Pam Klein may publish in the future.

Co-authorship network of co-authors of Pam Klein

This figure shows the co-authorship network connecting the top 25 collaborators of Pam Klein. A scholar is included among the top collaborators of Pam Klein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pam Klein. Pam Klein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Lee, Shing Yip, Amy Tiersten, Della Makower, et al.. (2021). Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. Breast Cancer Research and Treatment. 189(1). 177–185. 22 indexed citations

Alemany, Carlos, Manish R. Patel, Zahi Mitri, et al.. (2021). Abstract P037: A phase 1/2 dose escalation and expansion study of OP-1250 in adults with advanced and/or metastatic hormone receptor-positive (HR+), HER2-negative (HER2−) breast cancer. Molecular Cancer Therapeutics. 20(12_Supplement). P037–P037. 3 indexed citations

Infante, Jeffrey R., Josep Tabernero, Howard A. Burris, et al.. (2012). Abstract 5588: A phase I, open label, dose escalation study of an oral mammalian target of rapamycin inhibitor INK128 administered once daily in patients with advanced malignancies. Cancer Research. 72(8_Supplement). 5588–5588. 7 indexed citations

Jenkins, Jean, Eileen Dimond, David J. Liewehr, et al.. (2007). Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counseling. Genetics in Medicine. 9(8). 487–495. 56 indexed citations

Eberhard, David A., Bruce E. Johnson, Lukas C. Amler, et al.. (2005). Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib. Journal of Clinical Oncology. 23(25). 5900–5909. 1200 indexed citations breakdown →

Herbst, Roy S., Diane Prager, Róbert Hermann, et al.. (2005). TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 23(25). 5892–5899. 1204 indexed citations breakdown →

Allegra, Carmen J., Allyson L. Parr, Lester E. Wold, et al.. (2002). Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer. Journal of Clinical Oncology. 20(7). 1735–1743. 140 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact